Feline Leukemia Virus
Feline leukemia virus (FeLV) is a retrovirus, a family
of viruses which has many members that infect cats and cause disease and death
in cats around the world. Another well-known feline retrovirus is the feline immunodeficiency
virus (FIV). FeLV and FIV can be found together in the same cat.
Prevalence
The prevalence
of FeLV in single-cat households is about 3% and can be as high as 11% in stray
cat populations. In large multi-cat households and in households where cats roam
freely outdoors, the prevalence can reach as high as 70%. Cats roaming in urban
areas are more likely to be exposed to FeLV (40%) than cats roaming in rural areas
(6%).
Characteristics
FeLV has been studied for over 30 years, both for its
relevance to the cat population and because it serves as an animal model for some
human diseases.
Research has established key characteristics of FeLV: it is contagious,
it directly causes both fatal cancerous and non-cancerous diseases, it can lie
dormant in the bone marrow for a long time, and it can be protected against by
vaccination. FeLV is not transmissible to humans or animal species other than
the cat family.
FeLV is a fragile virus that does not survive in the
environment. Ordinary household detergents and bleach effectively kill this virus.
There is therefore no danger that cats can be exposed to FeLV in veterinary clinic
waiting rooms or exam rooms, or in cages, or at cat shows unless direct contact
is made with a positive cat who is shedding virus.
Transmission of FeLV requires
intimate moist contact. The most common route is contact with infected saliva
through grooming, licking, biting and shared dishes and litter pans. FeLV can
also be transmitted through a blood transfusion, so all cats who are blood donors
are screened for FeLV. Kittens can be infected by their mother before birth or
during nursing after birth.
Outcomes from Exposure
When a cat is exposed to FeLV, there are four possible
outcomes.
In about 30% of cats, an effective immune response is produced and the
infection is resisted. These cats then become naturally immune to FeLV infection
for an unknown period of time.
In about 40% of cats, the virus is successful and
the cat eventually becomes persistently infected and excreting virus in its saliva.
Another 30% of cats do not produce immunity but also do not become persistently
infected immediately. In these cats, the virus hides in the bone marrow for up
to 30 months. Eventually, these cats either overcome the virus or become persistently
infected.
Finally, some cats can develop latent or sequestered infection. This
probably happens to less than 5-10% of cats. These cats, whose virus is hiding
in sites such as the bone marrow, will rarely be contagious and are unlikely to
develop illness. They will not test positive on routine testing.
In general, young
cats, especially those under 4 months of age, have the least ability to mount
an effective immune response and so are most susceptible to FeLV.
Associated Diseases and Symptoms
FeLV is capable of producing a wide variety of associated
diseases and symptoms. Degenerative diseases, such as anemia, liver disease, intestinal
disease and reproductive problems can be seen. In other cats, the virus produces
cancerous diseases, such as lymphosarcoma and leukemia.
Many cats suffer from
suppression of the immune system and other illnesses, depending on which organ
is involved. Cats whose immune systems are depressed by FeLV are susceptible to
a wide variety of infectious diseases and other problems, such as chronic respiratory
infections, chronic gingivitis and stomatitis, feline infectious peritonitis,
poor healing of wounds and abscesses and chronic generalized infections.
Testing
Testing is the basis for diagnosing and managing FeLV
infections. The most common screening test for FeLV is the ELISA, while the immunofluorescent
antibody test (IFA) is the most common confirmatory test. Vaccination for FeLV
does not affect test results since the tests look for viral antigens, not antibodies.
Kittens can be tested at any age because maternal immunity does not interfere
with testing.
The ELISA is the preferred test for screening cats since it is quick
and readily available in vet clinics. It should be performed on a blood sample,
since ELISAs done on tears or saliva have been shown to be unreliable. Any positive
or equivocal ELISA test results should be confirmed using the IFA test, usually
done at a commercial laboratory. It is possible to have results on ELISA and IFA
which do not agree for a variety of reasons, and there is a testing protocol to
follow in order to determine the status of such cats.
The American Association of Feline Practitioners (AAFP)
have published recommendations for FeLV testing. The guidelines state that the
FeLV status of all cats should be known because FeLV is responsible for the illness
and death of more cats than any other disease condition. Testing and identifying
positive cats is the mainstay of FeLV control and is not replaced by vaccination.
Cats who have had a recent exposure to a known FeLV positive cat should be tested
as should any cats who are ill. Any new kitten or cat should be tested before
being added to a household with resident cats. Even if the household does not
already have resident cats, new pets should be tested because the emotional bond
that forms between owners and pets justifies knowing any future threats to the
pet’s health.
Living with FeLV
Cats who test positive for FeLV may live for months
to years. Euthanasia of positive cats must be addressed on an individual basis
in consultation with the veterinarian. In many cases, it is possible and feasible
to keep a positive cat and ensure good quality of life through the combined efforts
of the owner and the veterinarian.
Positive cats are capable of transmitting their
infection to other cats, so they should not live with other cats nor should they
be allowed to roam outside. This not only protects other cats from FeLV, but protects
the positive cat against the many diseases and illnesses they may contract due
to their increased susceptibility.
Treatment
The mainstays of treating FeLV positive cats are protecting
them from exposure to other diseases, ensuring good nutrition, giving regular
vaccinations with killed virus vaccines (but not with a feline leukemia vaccine),
reducing stress, controlling parasites, and early and aggressive treatment of
any symptoms that appear.
There is no specific treatment for FeLV and no known
cure. A large number of therapies have been investigated for FeLV positive cats,
but most have not shown encouraging results. Anti-viral drugs, such as AZT, show
some promise, but are associated with many side effects. A drug that stimulates
the immune system, interferon, can be given orally to cats without side effects
and may be helpful in many cases.
Experimental protocols have been developed that
combine AZT with interferon or interferon and another immunostimulant, Propionibacterium
acnes (Immunoregulin by ImmunoVet Inc, Tampa FL). Specific cancers associated
with FeLV have their own chemotherapy treatment protocols. However, cats with
cancer associated with FeLV have an average survival time of 6 months even with
aggressive chemotherapy. Drugs that are being developed to treat AIDS in humans
are often tested in cats first, so that studies on new drugs for AIDS may produce
drugs we can also use to treat FeLV in cats.
FeLV Test and Removal Program
The best protection against any infectious disease is
eliminating possible exposure. The FeLV test and removal program was developed
to remove infected cats from infected households. Using this program, no new cats
are added to the household and all resident cats are tested by IFA every 3 months.
Any cats with positive tests are removed from the household. When every cat tests
negative by IFA for two tests in a row, the household is declared free of FeLV.
Any new cats are not admitted to the household without a 3-month waiting period
in which they must have two negative IFA tests. This program has proven to be
very effective for multi-cat households and catteries.
Vaccines
There are presently a number of companies who make and
sell vaccines against FeLV. Vaccines may be against FeLV only, or they may combine
FeLV with other components. Many trials have been conducted to compare the effectiveness
of the various vaccines, but unfortunately, the studies remain hard to interpret,
largely due to inconsistencies in study designs.
On average, FeLV vaccines are
able to prevent infection in about 80 to 90% of cats. All the vaccines are recommended
to be given as a two-dose regimen spaced 2-4 weeks apart, staring with kittens
8 to 9 weeks of age. Thereafter, annual boosters are recommended.
Recently, the American Association of Feline Practitioners
has released feline vaccination guidelines. They divided vaccines into core and
non-core groups. Core vaccines are those felt to be necessary for all cats and
non-core vaccines are felt to be necessary only for those cats at realistic risk
of the disease. FeLV vaccines are designated as non-core vaccines.
Vaccination is recommended only for those cats whose lifestyle places them at risk for FeLV.
This includes outdoor cats or those that are indoor/outdoor, feral cats, cats
in open multi-cat households, cats in FeLV-positive households, and cats in households
where the FeLV status of all resident cats is not known.
Since young cats are
at the greatest risk and their lifestyle is most likely to change in the future,
the AAFP panel felt that it may be appropriate to suggest initial FeLV vaccination
for all kittens, with subsequent annual vaccinations only for those that continue
to be at-risk. In any case, owners should discuss issues of FeLV testing and vaccination
with their veterinarian so the best decision can be reached for each individual
cat.
by Susan Little, DVM, Diplomate ABVP (Feline) CFA Health Committee
References:
1.Colloquium on FeLV/FIV: Tests and Vaccination, Journal
of the American Veterinary Medical Assoc, Vol 199, No 10, 1991
2.Recommendations for Feline Leukemia Virus Testing,
American Association of Feline Practitioners Newsletter, Vol 14, No 1, April 1996
3.Feline Vaccination Guidelines, Advisory Panel on Feline
Vaccines of the American Association of Feline Practitioners and the Academy of
Feline Medicine, 1997
4.Weiss RC, Cummins JM, Richards, AB. Low-dose orally
administered alpha interferon treatment for feline leukemia virus infection. J
Amer Anim Hosp Assoc 199 (10): 1477-1481, 1991
5.Rojko JL, Hardy WD. Feline Leukemia Virus and other
retroviruses, in Sherding RG (ed), The cat: diseases and clinical management,
second edition, WB Saunders, Philadelphia, pp 263-432, 1994.